Evidence supporting the use of: Nicotinamide
For the health condition: Dementia

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Nicotinamide (also known as niacinamide, a form of vitamin B3) has gained some scientific interest as a potential supportive treatment in dementia, particularly Alzheimer’s disease. Preclinical studies in animal models have shown that nicotinamide can reduce tau phosphorylation and improve cognitive function. For example, a 2008 study in mice published in the journal Journal of Neuroscience found that nicotinamide administration improved cognitive deficits and reduced tau pathology associated with Alzheimer’s.

However, human clinical evidence is limited. A small pilot clinical trial in 2017 (Current Alzheimer Research) indicated that nicotinamide supplementation was safe and well-tolerated in patients with mild cognitive impairment, but did not show significant improvement in cognitive outcomes over placebo in the short term. Larger, well-powered clinical trials are lacking, and current guidelines do not recommend nicotinamide as a standard treatment for dementia.

In summary, while there is some scientific basis from animal studies and pilot human trials to justify further research into nicotinamide for dementia, robust clinical evidence supporting its efficacy in humans is insufficient at this time. Its use in dementia is therefore considered experimental and not standard practice.

More about Nicotinamide
More about Dementia

Products containing Nicotinamide

We currently have no products on Vitabase that contain this ingredient.